Phathom Pharmaceuticals (PHAT) announced that the Food and Drug Administration has approved the company’s citizen petition filed on December 11, 2024 and communicated the agency’s intention to correct the Orange Book to recognize the proper 10 years of new chemical entity exclusivity for Voquenza tablets, extending through May 3, 2032.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Phathom Pharmaceuticals price target lowered to $12 from $18 at Guggenheim
- Phathom Pharmaceuticals price target lowered to $20 from $28 at H.C. Wainwright
- Phathom Pharmaceuticals Reports Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue